NewEdge Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

NewEdge Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13K	Buy	+6,123	New	+$14.6K	﹤0.01%	3324
2025 Q4	–	Sell	-17	Closed	-$64	–	4228
2025 Q3	$64	Hold	17	–	–	﹤0.01%	4048
2025 Q2	$42	Hold	17	–	–	﹤0.01%	3937
2025 Q1	$26	Hold	17	–	–	﹤0.01%	3880
2024 Q4	$36	Hold	17	–	–	﹤0.01%	3829
2024 Q3	$74	Hold	17	–	–	﹤0.01%	3731
2024 Q2	$79	Hold	17	–	–	﹤0.01%	3697
2024 Q1	$86	Hold	17	–	–	﹤0.01%	3708
2023 Q4	$48	Hold	17	–	–	﹤0.01%	3670
2023 Q3	$49	Hold	17	–	–	﹤0.01%	3401
2023 Q2	$86	Hold	17	–	–	﹤0.01%	3426
2023 Q1	$32	Sell	17 -96	-85%	-$221	﹤0.01%	3373
2022 Q4	$173	Buy	+113	New	+$204	﹤0.01%	3315

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

NewEdge Advisors's BDTX Position: Q1 2026 in Review

NewEdge Advisors opened a new position in Black Diamond Therapeutics (BDTX) in Q1 2026: 6,123 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #3324 among its holdings. This is a return to the name: NewEdge Advisors previously reported a position in BDTX as recently as Q3 2025.

NewEdge Advisors first reported a position in BDTX in Q4 2022 and has held it in 13 quarters since. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

NewEdge Advisors held 6,123 shares of Black Diamond Therapeutics worth $13K as of Q1 2026.
Black Diamond Therapeutics was a new NewEdge Advisors position in Q1 2026.
Black Diamond Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3324 holding.
NewEdge Advisors first reported a position in Black Diamond Therapeutics in Q4 2022 and has held it in 13 quarters since.
104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.